Company: SCLXW
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0000950170-25-071920
Chunk: 62

Company: Scilex Holding Co
Filing Date: 2025-05-15
Form: 424B3
Chunk 62
---
| April 2024 RDO Common Warrants            |     |           |   428,572 |     |              |         — |
| April 2024 RDO Placement Agent Warrants   |     |           |    34,286 |     |              |    34,286 |
| Deposit Warrants                          |     |           | 3,250,000 |     |              |         — |
| October 2024 Noteholder Warrants          |     |           |   214,284 |     |              |         — |
| October 2024 Placement Agent Warrants     |     |           |   104,848 |     |              |   104,848 |
| December 2024 RDO Common Warrants         |     |           | 1,642,871 |     |              | 1,642,871 |
| StockBlock Warrants                       |     |           |   131,472 |     |              |   131,472 |
| Total                                     |     |           | 8,668,507 |     |              | 4,817,769 |

<div align='center'>34</div>

13. Subsequent Events

Scilex Bio JV

On April 17, 2025, the Company and IPMC Company formed a joint venture, Scilex Bio, Inc., to develop and commercialize a next-generation reversible MAO-B Inhibitor, a novel inhibitor of aberrant GABA production in reactive astrocytes for the treatment of obesity and neurodegenerative diseases including Alzheimer’s disease. The Company contributed 5.0 million shares of Semnur Common Stock owned by the Company to Scilex Bio, Inc. in exchange for a 60% ownership interest in Scilex Bio, Inc. and IPMC Company contributed certain assets to Scilex Bio, Inc. in exchange for a 40% ownership interest in Scilex Bio, Inc. In connection with the formation of Scilex Bio, Inc. and the related transactions, on April 16, 2025, the Company entered into a Consent, Waiver and Amendment re Tranche A Senior Secured Promissory Note with Oramed, and the Company entered into a Consent, Waiver and Amendment re Tranche B Senior Secured Convertible Note with each of the Tranche B Noteholders.

<div align='center'>35</div>

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of